Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 49 for:    Sodium Lauryl Sulfate

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01821274
Recruitment Status : Unknown
Verified July 2013 by Ventrus Biosciences, Inc.
Recruitment status was:  Active, not recruiting
First Posted : March 29, 2013
Last Update Posted : August 21, 2013
Sponsor:
Information provided by (Responsible Party):
Ventrus Biosciences, Inc

Tracking Information
First Submitted Date  ICMJE March 26, 2013
First Posted Date  ICMJE March 29, 2013
Last Update Posted Date August 21, 2013
Study Start Date  ICMJE March 2013
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 28, 2013)
Mean cumulative irritation score of Diltiazem Hydrochloride 2% Cream in healthy skin of humans. [ Time Frame: 21 days ]
The primary variable of interest is the mean cumulative irritation score. The mean cumulative irritation score for each subject, product and site will be calculated as the sum of the irritation scores divided by the number of readings. The total cumulative irritation score for each subject and product will also be calculated as the sum of irritation scores on each of 21 evaluation days. A normalized total score for each patch will be calculated by summing the total irritation scores for all subjects, dividing by the number of readings and multiplying by 210. These parameters will be tested pairwise for product differences using Fisher's protected least significant differences in the context of the analysis of variance (ANOVA), including effects of subject and product (ie, randomized complete blocks). All pairwise differences will be tested. No adjustment for multiple comparisons will be made.
Original Primary Outcome Measures  ICMJE
 (submitted: March 26, 2013)
Determine the potential of Diltiazem Hydrochloride 2% Cream to cause irritation after repeated topical application to the healthy skin of humans under controlled conditions. [ Time Frame: 21 days ]
Individual irritancy scores will be displayed in a data listing for all subjects, study products, and readings. Frequency counts of each assigned score at each reading for each product will be presented, along with the mean and total of the scores. The mean cumulative irritation score for each subject, product and site will be calculated as the sum of the irritation scores divided by the number of readings. The total cumulative irritation score for each subject and product will also be calculated as the sum of irritation scores on each of 21 evaluation days.
Change History Complete list of historical versions of study NCT01821274 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design
Official Title  ICMJE A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects, Using a Cumulative Irritant Patch Test Design
Brief Summary The purpose of the study is to determine whether Diltiazem Hydrochloride 2% Cream will cause irritation to skin on the back of healthy volunteers after repeated application over 21-days.
Detailed Description

The primary objective of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream to cause irritation after repeated topical application to the healthy skin of humans under controlled conditions.

In addition, safety will be assessed by evaluation of any adverse events (AEs) reported during the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Skin Irritation
Intervention  ICMJE
  • Drug: Diltiazem Hydrochloride 2% Cream
    0.2 g applied topically to the infrascapular area of the back.
  • Drug: Vehicle Cream
    0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
  • Drug: 0.1% solution o sodium lauryl sulfate (SLS)
    0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
  • Drug: Saline 0.9%
    0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
Study Arms  ICMJE
  • Experimental: topical Diltiazem Hydrochloride 2% Cream
    0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
    Intervention: Drug: Diltiazem Hydrochloride 2% Cream
  • Placebo Comparator: Vehicle Cream
    0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
    Intervention: Drug: Vehicle Cream
  • Active Comparator: 0.2% sodium lauryl sulfate (SLS)
    0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
    Intervention: Drug: 0.1% solution o sodium lauryl sulfate (SLS)
  • Placebo Comparator: 0.9% saline
    0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
    Intervention: Drug: Saline 0.9%
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: March 26, 2013)
30
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2013
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Are healthy males or females (to be confirmed by medical history)
  • Are 18 years of age or older
  • In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes
  • If a female of childbearing potential, have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at end of study (EOS)
  • Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events
  • Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema
  • Complete a Medical Screening form as well as a Medical Personal History form
  • Read, understand, and provide signed informed consent

Exclusion Criteria:

  • Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history
  • Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history)
  • Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs)
  • Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history)
  • Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction
  • Are not willing to refrain from using systemic/topical analgesics such as aspirin (81 mg daily aspirin will be allowed), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to Day 1 and during the study (occasional use of acetaminophen will be permitted)
  • Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to Day 1 and during the study
  • Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications
  • Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study
  • Have psoriasis and/or active atopic dermatitis/eczema
  • Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child
  • Have a known sensitivity to constituents present in the material being evaluated
  • Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site
  • Have received treatment for any type of internal cancer within 5 years prior to study entry
  • Have a history of, or are currently being treated for skin cancer
  • Are currently participating in any clinical testing
  • Have any known sensitivity to adhesives
  • Have received any investigational treatment(s) within 4 weeks prior to study entry
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01821274
Other Study ID Numbers  ICMJE VEN307-DERM-002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ventrus Biosciences, Inc
Study Sponsor  ICMJE Ventrus Biosciences, Inc
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Ventrus Biosciences, Inc
Verification Date July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP